Document is current
Any future updates will be listed below
-
Authors
Figarol, Sarah https://orcid.org/0000-0002-3863-563X
Delahaye, Célia https://orcid.org/0009-0004-7966-5597
Gence, Rémi
Doussine, Aurélia
Cerapio, Juan Pablo https://orcid.org/0000-0002-3032-3180
Brachais, Mathylda
Tardy, Claudine
Béry, Nicolas https://orcid.org/0000-0002-2643-3897
Asslan, Raghda
Colinge, Jacques https://orcid.org/0000-0003-2466-4824
Villemin, Jean-Philippe
Maraver, Antonio https://orcid.org/0000-0002-5527-5680
Ferrer, Irene https://orcid.org/0000-0002-2748-2607
Paz-Ares, Luis
Kessler, Linda
Burrows, Francis
Lajoie-Mazenc, Isabelle
Dongay, Vincent
Morin, Clara
Florent, Amélie
Pagano, Sandra https://orcid.org/0000-0003-1758-3233
Taranchon-Clermont, Estelle
Casanova, Anne
Pradines, Anne
Mazieres, Julien https://orcid.org/0000-0002-5921-7613
Favre, Gilles https://orcid.org/0000-0002-2344-1883
Calvayrac, Olivier https://orcid.org/0000-0002-0908-8323
-
Funding
Funding for this research was provided by:
Fondation ARC pour la Recherche sur le Cancer (PJA2)
Fondation pour la Recherche Médicale (DEQ20170839117, DEQ20170839117, DEQ20170839117)
Institut National de la Santé et de la Recherche Médicale (Inserm, Inserm)
Fondation Toulouse Cancer Santé (FTCS), Labex TOUCAN, ALK+ &ROS1 France patient association (donation), Kura Oncology
Institut National Du Cancer (PRT-K18-048)
Ligue Contre le Cancer (LNCC)
- License Information
-
More Information
Article History
Received: 2 March 2024
Accepted: 3 June 2024
First Online: 27 June 2024
Competing interests
: O.C. reports research funding from Kura Oncology through a sponsored research contract. L.K. reports personal fees from Kura Oncology during the conduct of the study and personal fees from Kura Oncology outside the submitted work. FB is an employee and stockholder of Kura Oncology. JM reports personal fees/advisory board membership from Roche and Bristol Myers Squibb, and AstraZeneca, advisory board membership and research funding (institution), personal fees/advisory board membership from Pfizer, Novartis, Amgen, Takeda, Daiichi Sankyo, the healthcare business of Merck KGaA, Darmstadt, Germany, grants/funding (institution) from Roche/Genentech, Bristol Myers Squibb, Pierre Fabre and AstraZeneca outside the submitted work. L.P.A has leadership interest (board member) in ALTUM Sequencing and Genomica; has received honoraria for participation at meetings from Amgen Sanofi, AstraZeneca Spain, Bayer, Blueprint Medicines, Bristol Myers Squibb/Celgene, Daiichi Sankyo, Ipsen, Lilly, Merck Serono, Mirati Therapeutics, Novartis, Pfizer, PharmaMar, Roche/Genentech, Servier, and Takeda; speakers’ bureau from AstraZeneca, Bristol Myers Squibb, Merck Serono, MSD Oncology, Pfizer, and Roche/Genentech; research funding (via his institution) from AstraZeneca, Bristol Myers Squibb, Kura Oncology, MSD, Pfizer and PharmaMar; and travel and accommodation expenses from AstraZeneca, Bristol Myers Squibb/Celgene, MSD, Pfizer Roche/Genentech, and Takeda. L.P-A. also declares other relationships with Amgen, Ipsen, Merck, Novartis, Pfizer, Roche, Sanofi, and Servier (as sponsors of clinical trials), outside the submitted work. The remaining authors declare no conflict of interest.
